To elucidate the signaling mechanisms involved in the retinal arteriolar dilation induced by resveratrol, the following series of experiments were performed. The role of endothelium in the resveratrol-induced dilation was evaluated by comparing the response before and after removal of the endothelium. The vessel was perfused with a nonionic detergent, 3-[(3-cholamidopropyl) dimethylammonio]-1 propane sulfonate (CHAPS; 0.4%), for 1 to 2 minutes, to remove endothelial cells.
21 25 To ensure that the vascular smooth muscle function was not compromised by the CHAPS treatment, dose-dependent dilation of the vessel in response to the endothelium-independent vasodilator sodium nitroprusside (0.1–100 μM) was examined before and after denudation. Only vessels that exhibited normal basal tone showed no vasodilation in response to endothelium-dependent vasodilator bradykinin (10 nM),
26 and that showed unaltered vasodilation in response to sodium nitroprusside after removal of the endothelium were accepted for further study with resveratrol. The involvement of endothelium-derived vasodilators (i.e., prostaglandins, NO, and cytochrome P450 metabolites) in mediating the vascular response was assessed in the presence of known effective concentrations of the specific enzyme inhibitors indomethacin (10 μM),
20 27 N G-nitro-
l-arginine methyl ester (
l-NAME; 10 μM),
19 20 and sulfaphenazole (10 μM),
28 respectively. The role of guanylyl cyclase/cGMP signaling was assessed by treating the vessels with the soluble guanylyl cyclase inhibitor 1H-1,2,4-oxadiazolo[4,3-a]quinoxalin-1-one (ODQ, 0.1 μM),
20 21 in the absence or presence of the cGMP phosphodiesterase inhibitor zaprinast (1 μM).
20 To probe the involvement of extracellular signal-regulated kinase (ERK), we studied the resveratrol-induced response after incubating the vessels with the ERK inhibitor PD98059 (1 μM).
29 Since activation of potassium channels is known to be a major mechanism in vasodilation,
30 we examined this pathway by treating the vessels with various potassium channel inhibitors: the nonselective potassium channel blocker tetraethylammonium (TEA, 20 mM), the large-conductance Ca
2+-activated potassium (BK
Ca) channel blocker iberiotoxin (0.1 μM),
31 32 the voltage-gated K
+ (K
V) channel inhibitor 4-aminopyridine (4-AP, 0.1 mM),
33 or the ATP-sensitive potassium (K
ATP) channel blocker glibenclamide (5 μM).
20 TEA has been reported to inhibit BK
Ca channels selectively at concentrations lower than 1 mM, while blocking other potassium channels at higher concentrations (i.e., up to 10 mM).
31 Because resveratrol is structurally similar to the synthetic estrogen diethylstilbestrol,
34 we examined the role of estrogen receptors in the effect of resveratrol. The isolated vessels were pretreated intraluminally with the estrogen receptor antagonist ICI 182780 (1 μM) for 30 minutes before we examined the resveratrol-induced response.
35 Sodium nitroprusside (1 nM to 10 μM) was used to probe endothelium-independent NO-mediated vasodilation. All drugs were administered extraluminally, unless otherwise stated. Each pharmacologic inhibitor was incubated with the vessels for at least 30 minutes.